SCHEMBL426399

SCHEMBL426399

CC1C(=O)CC1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 1/20 0.51
ATM Q13315 1/20 0.51
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
MAOB P27338 8/20 0.41
MAOA P21397 7/20 0.41
KDM1A O60341 5/20 0.41
CYP2C19 P33261 4/20 0.41
CYP2B6 P20813 3/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
LMNA P02545 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
CYP3A4 P08684 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21821886 0.84 MAPT (0.50) SMN1; SMN2ALDH1A1ATMGAAMAPT
SCHEMBL25554138 0.81 ATM (0.46) SMN1; SMN2ALDH1A1ATMMAPTMAOB
SCHEMBL24818038 0.79 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1ATMSIGMAR1MAOB
SCHEMBL11473867 0.76 MT-CO2 (0.43) SMN1; SMN2ALDH1A1ATM
SCHEMBL24820969 0.76 MT-CO2 (0.43) SMN1; SMN2ALDH1A1ATM
SCHEMBL24806685 0.76 MT-CO2 (0.43) SMN1; SMN2ALDH1A1ATM
SCHEMBL25025572 0.75 HTR2C (0.44) SIGMAR1MAOBKDM1ACYP2D6CYP3A4
SCHEMBL23278853 0.75 PARP3 (0.43) SMN1; SMN2ALDH1A1ATMGAAMAPT
SCHEMBL25048674 0.72 CYP2C19 (0.40) SMN1; SMN2ALDH1A1ATMGAAMAPT
SCHEMBL25799655 0.72 SIGMAR1 (0.44) SMN1; SMN2ALDH1A1ATMSIGMAR1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2481735-A1 Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials Pfizer Inc. (US) 2012-08-01 EP disclosed
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2012-03-15 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions PFIZER INC. 2011-04-21 US disclosed
WO-2008139288-A2 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND COMPOSITIONS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS PFIZER INC. (US) 2008-11-20 WO disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065188-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 SMN1; SMN2 4085/4885ALDH1A1 3777/4885ATM 3824/4885
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 SMN1; SMN2 4085/4885ALDH1A1 3777/4885ATM 3824/4885
US-20110092480-A1 Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions XDH, CYP2D6, F12 SMN1; SMN2 4085/4885ALDH1A1 3777/4885ATM 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.